Vol 17, No 6 (2021)
Research paper
Published online: 2021-06-16
Results of darbepoetin alfa treatment of anaemia in chemotherapy-receiving breast cancer patients: a single-centre retrospective observational study
Oncol Clin Pract 2021;17(6):237-243.
Abstract
A retrospective observational study of the outcomes of darbepoetin alfa treatment for chemotherapy-induced anaemia in breast cancer patients was conducted. A group of 152 patients treated during 13 months in one oncology centre was assessed. Ninety-eight patients (64.5%) received perioperative chemotherapy, and 54 patients (35.5%) received palliative chemotherapy. The results of treatment with darbepoetin alfa were analysed by age ( < 65 vs. ≥ 65 years), the aim of chemotherapy (perioperative vs. palliative), and body mass index ( < 25 vs. 25–29 vs. 30 and more). The effectiveness of the therapy was estimated at 80.9% (95% CI: 74.7–87.2%). Significantly higher effectiveness of ESA was found in patients treated perioperatively compared to patients treated for metastatic breast cancer (85.7% vs. 72.2%, p = 0.043). There were no differences in the effectiveness of ESA depending on age and BMI. No serious ESA-related adverse events were observed.
Keywords: chemotherapy-induced anaemiabreast cancerdarbepoetin alfaerythropoietin-stimulating agents
References
- Macdougall IC. Novel erythropoiesis-stimulating agents: a new era in anemia management. Clin J Am Soc Nephrol. 2008; 3(1): 200–207.
- Aapro MS. Editorial: anemia management with erythropoiesis-stimulating agents: a risk-benefit update. Oncologist. 2008; 13 Suppl 3: 1–3.
- Stramer SL. Current risks of transfusion-transmitted agents: a review. Arch Pathol Lab Med. 2007; 131(5): 702–707.
- Bernard AC, Davenport DL, Chang PK, et al. Intraoperative transfusion of 1 U to 2 U packed red blood cells is associated with increased 30-day mortality, surgical-site infection, pneumonia, and sepsis in general surgery patients. J Am Coll Surg. 2009; 208: 931–937.
- Ludwig H, Van Belle S, Barrett-Lee P, et al. The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur J Cancer. 2004; 40(15): 2293–2306.
- Cella D, Kallich J, McDermott A, et al. The longitudinal relationship of hemoglobin, fatigue and quality of life in anemic cancer patients: results from five randomized clinical trials. Ann Oncol. 2004; 15(6): 979–986.
- Caro JJ, Salas M, Ward A, et al. Anemia as an independent prognostic factor for survival in patients with cancer: a systemic, quantitative review. Cancer. 2001; 91(12): 2214–2221.
- Radziwon P, Krzakowski M, Kalinka-Warzocha E, et al. Anemia in cancer patients — Expert Group recommendations. Oncol Clin Pract. 2017; 13(202): 210.
- Aapro M, Beguin Y, Bokemeyer C, et al. ESMO Guidelines Committee, ESMO Guidelines Committee. Management of anaemia and iron deficiency in patients with cancer: ESMO Clinical Practice Guidelines. Ann Oncol. 2018; 29(Suppl 4): iv96–iv9iv110.
- https://www.eortc.be/services/doc/ctc/CTCAE_4.03_2010-06 14_QuickReference_5x7.pdf.
- htps://www.ema.europa.eu/en/documents/product-information/aranesp-epar-product-information_pl.pdf.
- Moebus V, Jackisch C, Schneeweiss A, et al. AGO Breast Study Group. Adding epoetin alfa to intense dose-dense adjuvant chemotherapy for breast cancer: randomized clinical trial. J Natl Cancer Inst. 2013; 105(14): 1018–1026.
- Sabir S, Khan YH, Khatoon M, et al. Effect of Erythropoiesis Stimulating Agents on Clinical Outcomes in Breast Cancer Patients: A Systematic Review of Randomised Controlled Trials. J Coll Physicians Surg Pak. 2020; 30(3): 292–298.
- Groopman JE, Itri LM. Chemotherapy-induced anemia in adults: incidence and treatment. J Natl Cancer Inst. 1999; 91(19): 1616–1634.
- Valero V, Holmes FA, Walters RS, et al. Phase II trial of docetaxel: a new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer. J Clin Oncol. 1995; 13(12): 2886–2894.
- Link H. Hematopoietic Growth Factors in the Management of Anemia and Febrile Neutropenia. Breast Care (Basel). 2019; 14(2): 93–98.
- Van Belle S, Karanikiotis C, Labourey JL, et al. Current practice of darbepoetin alfa in the management of haemoglobin levels in cancer patients undergoing chemotherapy - data from the CHOICE study. Curr Med Res Opin. 2011; 27(5): 987–994.
- Vansteenkiste J, Pirker R, Massuti B, et al. Aranesp 980297 Study Group. Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy. J Natl Cancer Inst. 2002; 94(16): 1211–1220.
- Hedenus M, Birgegård G, Näsman P, et al. Addition of intravenous iron to epoetin beta increases hemoglobin response and decreases epoetin dose requirement in anemic patients with lymphoproliferative malignancies: a randomized multicenter study. Leukemia. 2007; 21(4): 627–632.
- Glaspy J, Bukowski R, Steinberg D, et al. Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. Procrit Study Group. J Clin Oncol. 1997; 15(3): 1218–1234.
- Pedrazzoli P, Farris A, Del Prete S, et al. Randomized trial of intravenous iron supplementation in patients with chemotherapy-related anemia without iron deficiency treated with darbepoetin alpha. J Clin Oncol. 2008; 26(10): 1619–1625.
- Massa E, Madeddu C, Lusso MR, et al. Evaluation of the effectiveness of treatment with erythropoietin on anemia, cognitive functioning and functions studied by comprehensive geriatric assessment in elderly cancer patients with anemia related to cancer chemotherapy. Crit Rev Oncol Hematol. 2006; 57(2): 175–182.
- Kurtz JE, Soubeyran P, Michallet M, et al. Biosimilar epoetin for the management of chemotherapy-induced anemia in elderly patients. Onco Targets Ther. 2016; 9: 6689–6693.
- Berbec NM, Stanculeanu DL, Badelita NS, et al. APPLY: A prospective observational study of clinical practice patterns of darbepoetin alfa use in patients with chemotherapy-induced anemia in Romania. Memo. 2018; 11(2): 144–151.
- https://www.mp.pl/interna/chapter/B16.IV.24.21.
- Welsh L, Panek R, Riddell A, et al. Blood transfusion during radical chemo-radiotherapy does not reduce tumour hypoxia in squamous cell cancer of the head and neck. Br J Cancer. 2017; 116(1): 28–35.
- Meybohm P, Herrmann E, Steinbicker AU, et al. Patient blood management is associated with a substantial reduction of red blood cell utilization and safe for patient’s outcome: a prospective, multicenter cohort study with a noninferiority design. Ann Surg. 2016; 264: 203–211.
- Aapro M, Moebus V, Nitz U, et al. Safety and efficacy outcomes with erythropoiesis-stimulating agents in patients with breast cancer: a meta-analysis. Ann Oncol. 2015; 26(4): 688–695.
- Chavez-MacGregor M, Zhao H, Fang S, et al. Complications associated with erythropoietin-stimulating agents in patients with metastatic breast cancer: a Surveillance, Epidemiology, and End Results-Medicare study. Cancer. 2011; 117(16): 3641–3649.
- Leyland-Jones B, Bondarenko I, Nemsadze G, et al. A Randomized, Open-Label, Multicenter, Phase III Study of Epoetin Alfa Versus Best Standard of Care in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy. J Clin Oncol. 2016; 34(11): 1197–1207.